XTRA:ECX

Stock Analysis Report

NOT FOR DISTRIBUTION
Header cover image

Executive Summary

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia.


Snowflake Analysis

Adequate balance sheet and slightly overvalued.


Similar Companies

Share Price & News

How has Epigenomics's share price performed over time and what events caused price changes?


Latest Share Price and Events

Stable Share Price: ECX's share price has been volatile over the past 3 months.


Market Performance


7 Day Return

-6.0%

ECX

-1.3%

DE Biotechs

2.6%

DE Market


1 Year Return

-42.3%

ECX

9.4%

DE Biotechs

0.5%

DE Market

Return vs Industry: ECX underperformed the German Biotechs industry which returned 9.4% over the past year.

Return vs Market: ECX underperformed the German Market which returned -0.2% over the past year.


Shareholder returns

ECXIndustryMarket
7 Day-6.0%-1.3%2.6%
30 Day-5.7%14.0%7.6%
90 Day-19.1%11.1%-1.7%
1 Year-40.4%-42.3%9.7%9.4%2.2%0.5%
3 Year-82.1%-83.6%14.5%13.0%-4.8%-12.1%
5 Year-76.8%-78.8%20.5%18.3%7.8%-6.0%

Price Volatility Vs. Market

How volatile is Epigenomics's share price compared to the market and industry in the last 5 years?


Simply Wall St News

Valuation

Is Epigenomics undervalued compared to its fair value and its price relative to the market?

>50%

Undervalued compared to fair value


Share Price vs. Fair Value

Below Fair Value: ECX (€1.22) is trading below our estimate of fair value (€3.3)

Significantly Below Fair Value: ECX is trading below fair value by more than 20%.


Price To Earnings Ratio

PE vs Industry: ECX is unprofitable, so we can't compare its PE Ratio to the Biotechs industry average.

PE vs Market: ECX is unprofitable, so we can't compare its PE Ratio to the German market.


Price to Earnings Growth Ratio

PEG Ratio: Insufficient data to calculate ECX's PEG Ratio to determine if it is good value.


Price to Book Ratio

PB vs Industry: ECX is overvalued based on its PB Ratio (8.5x) compared to the DE Biotechs industry average (5x).


Next Steps

Future Growth

How is Epigenomics forecast to perform in the next 1 to 3 years based on estimates from 2 analysts?

23.5%

Forecasted annual earnings growth


Earnings and Revenue Growth Forecasts


Analyst Future Growth Forecasts

Earnings vs Savings Rate: ECX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: ECX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: ECX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: ECX's revenue (63% per year) is forecast to grow faster than the German market (5.8% per year).

High Growth Revenue: ECX's revenue (63% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if ECX's Return on Equity is forecast to be high in 3 years time


Next Steps

Past Performance

How has Epigenomics performed over the past 5 years?

-9.8%

Historical annual earnings growth


Earnings and Revenue History

Quality Earnings: ECX is currently unprofitable.

Growing Profit Margin: ECX is currently unprofitable.


Past Earnings Growth Analysis

Earnings Trend: ECX is unprofitable, and losses have increased over the past 5 years at a rate of -9.8% per year.

Accelerating Growth: Unable to compare ECX's earnings growth over the past year to its 5-year average as it is currently unprofitable

Earnings vs Industry: ECX is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (17.1%).


Return on Equity

High ROE: ECX has a negative Return on Equity (-270.79%), as it is currently unprofitable.


Next Steps

Financial Health

How is Epigenomics's financial position?


Financial Position Analysis

Short Term Liabilities: ECX's short term assets (€11.8M) exceed its short term liabilities (€6.6M).

Long Term Liabilities: ECX's short term assets (€11.8M) exceed its long term liabilities (€687.0K).


Debt to Equity History and Analysis

Debt Level: ECX is debt free.

Reducing Debt: ECX has no debt compared to 5 years ago when its debt to equity ratio was 38.2%.


Balance Sheet


Cash Runway Analysis

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

Stable Cash Runway: ECX has less than a year of cash runway based on its current free cash flow.

Forecast Cash Runway: ECX has less than a year of cash runway if free cash flow continues to reduce at historical rates of 10.3% each year


Next Steps

Dividend

What is Epigenomics's current dividend yield, its reliability and sustainability?


Dividend Yield vs Market

Notable Dividend: Unable to evaluate ECX's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.

High Dividend: Unable to evaluate ECX's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.


Stability and Growth of Payments

Stable Dividend: Insufficient data to determine if ECX's dividends per share have been stable in the past.

Growing Dividend: Insufficient data to determine if ECX's dividend payments have been increasing.


Current Payout to Shareholders

Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.


Future Payout to Shareholders

Future Dividend Coverage: No need to calculate the sustainability of ECX's dividend in 3 years as they are not forecast to pay a notable one for the German market.


Next Steps

Management

How experienced are the management team and are they aligned to shareholders interests?

3.2yrs

Average management tenure


CEO

Greg Hamilton (49yo)

3.92yrs

Tenure

€877,600

Compensation

Mr. Gregory Hamilton, also known as Greg, has been the Chief Executive Officer and Member of Executive Board at Epigenomics AG since July 1, 2016. Mr. Hamilton has over 20 years of management experience in ...


CEO Compensation Analysis

Compensation vs Market: Greg's total compensation ($USD976.52K) is above average for companies of similar size in the German market ($USD423.20K).

Compensation vs Earnings: Greg's compensation has been consistent with company performance over the past year.


Leadership Team

NamePositionTenureCompensationOwnership
Gregory Hamilton
CEO & Member of the Executive Board3.92yrs€877.60k0.045% 24.8k
Jorge Garces
President2.5yrs€825.64k0.0021% 1.2k
Albert Weber
Executive VP of Finance & Member of the Executive Board2.42yrs€327.88k0.00021% 115.3
Peter Vogt
Vice President of Corporate Communications & Investor Relationsno datano datano data
Noel Doheny
Chief Executive Officer of Epigenomics Inc.9.08yrsno datano data
Frederic Hilke
Investor Relations Officerno datano datano data

3.2yrs

Average Tenure

49yo

Average Age

Experienced Management: ECX's management team is considered experienced (3.2 years average tenure).


Board Members

NamePositionTenureCompensationOwnership
Ann Kessler
Independent Deputy Chairwoman of the Supervisory Board8.08yrs€52.00k0.29% 160.3k
Günther Reiter
Independent Vice-Chairman of the Supervisory Board5.58yrs€52.00kno data
Heino von Prondzynski
Independent Chairman of the Supervisory Board8.08yrs€102.00k1.03% 565.0k
Helge Lubenow
Member of the Supervisory Board4.08yrs€47.00k0.037% 20.4k
Franz Walt
Member of the Supervisory Board1.08yrs€28.42k0.041% 22.7k

5.6yrs

Average Tenure

70yo

Average Age

Experienced Board: ECX's board of directors are considered experienced (5.6 years average tenure).


Ownership

Who are the major shareholders and have insiders been buying or selling?


Insider Trading Volume

Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.


Ownership Breakdown

Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 30.8%.


Top Shareholders

Company Information

Epigenomics AG's company bio, employee growth, exchange listings and data sources


Key Information

  • Name: Epigenomics AG
  • Ticker: ECX
  • Exchange: XTRA
  • Founded: 1998
  • Industry: Biotechnology
  • Sector: Pharmaceuticals & Biotech
  • Market Cap: €54.906m
  • Shares outstanding: 47.13m
  • Website: https://www.epigenomics.com

Number of Employees


Location

  • Epigenomics AG
  • Geneststrasse 5
  • Berlin
  • Berlin
  • 10829
  • Germany

Listings

TickerExchangePrimary SecuritySecurity TypeCountryCurrencyListed on
EPGN.FOTCPK (Pink Sheets LLC)Common SharesUSUSDJul 2004
EPGN.YOTCPK (Pink Sheets LLC)SPONSORED ADRUSUSDJul 2013
ECXDB (Deutsche Boerse AG)YesRegistered SharesDEEURSep 2014
ECXXTRA (XETRA Trading Platform)YesRegistered SharesDEEURSep 2014
0QXHLSE (London Stock Exchange)YesRegistered SharesGBEURSep 2014
ECXDBATS-CHIXE (BATS 'Chi-X Europe')YesRegistered SharesGBEURSep 2014
ECXETLX (Eurotlx)YesRegistered SharesITEURSep 2014

Biography

Epigenomics AG, a cancer molecular diagnostics company, develops and commercializes blood-based diagnostic tests across multiple cancer indications with high medical needs in Europe, North America, and Asia. Its lead product is Epi proColon, a blood-based test for the early detection of colorectal cancer using its proprietary DNA methylation biomarker, Septin9. The company also offers Epi proLung, a liquid biopsy test for lung cancer detection; and Epi BiSKit, a pre-analytical tool provides set of reagents for the preparation of bisulfite-converted DNA. Its development pipeline also contains products for screening, early detection, and diagnosis of colorectal and lung cancers. In addition, the company engages in the research and identification of additional DNA methylation biomarkers for prostate, bladder, breast, and ovarian cancers. Epigenomics AG was founded in 1998 and is headquartered in Berlin, Germany. 


Company Analysis and Financial Data Status

All financial data provided by Standard & Poor's Capital IQ.
DataLast Updated (UTC time)
Company Analysis2020/06/02 23:58
End of Day Share Price2020/06/02 00:00
Earnings2020/03/31
Annual Earnings2019/12/31


Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.